June 2025 Volume 21, Issue 2
Volume 21, Issue 2 | June 2025
June 2025
In this Issue
Mass Spectrometry
The future of tuberculosis diagnosis: using breath to fight disease spread
Researchers are developing new, portable breath analysis tools to diagnose tuberculosis and other diseases, making screenings more accessible in remote areas and beyond.
Mapping proteins to reveal secret drug binding pockets
Chemoproteomic tools are yielding early drug candidates for previously undruggable proteins.
Annihilating PFAS with an AI-designed enzyme
Using artificial intelligence and machine learning, a team of researchers engineered an enzyme to degrade toxic PFAS molecules — and they’re only in high school.Gene Editing
Gene-edited stem cells aim to reverse rheumatoid arthritis
A new approach for gene editing will get its shot in a common and chronic autoimmune disorder.
Epigenetic editing expands the reach of gene therapy
Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms.
Curing rare childhood blindness with a special gene therapy
Via a unique regulatory route in the UK, scientists found that a gene therapy restored vision in young kids with a very rare and severe retinal dystrophy.Antibody Drugs
The quest for an HIV cure: How broadly neutralizing antibodies are revolutionizing treatment and prevention
Explore how broadly neutralizing antibodies (bNAbs) are offering a new path to an HIV cure by targeting the latent HIV reservoir and preventing transmission.
Ending allergies at the source with a pair of antibody drugs
With new insight into IgE biology, a new, two-pronged strategy for eliminating the pathogenic immune cells that lead to allergies emerges.Ophthamology
New AMD treatments: a race to prevent blindness and vision loss
Learn about the latest advances in age-related macular degeneration (AMD) treatment, including a new drug that targets beta-amyloid to help prevent blindness and vision loss.Editor's Insight
